2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07C.05 Perioperative (Neoadjuvant Plus Adjuvant) Immunotherapies for Resectable NSCLC:A Systematic Review and Meta-Analysis of Phase 3 Trials

P2.07C.05 Perioperative (Neoadjuvant Plus Adjuvant) Immunotherapies for Resectable NSCLC:A Systematic Review and Meta-Analysis of Phase 3 Trials

Back to course

Pdf Summary

This systematic review and meta-analysis examines phase III trials concerning perioperative immunotherapies for patients with resectable non-small cell lung cancer (NSCLC). The review specifically assesses the efficacy and safety of neoadjuvant plus adjuvant immunotherapies compared to perioperative chemotherapy.<br /><br />The analysis involved a comprehensive search of databases such as PubMed, Embase, and Cochrane Library, leading to the inclusion of five trials encompassing 2,855 patients. Among them, 1,420 patients received perioperative immunotherapy, while 1,435 underwent chemotherapy. The trials investigated different immunotherapy regimens, including Durvalumab, Pembrolizumab, Nivolumab, Toripalimab, and Tislelizumab.<br /><br />The results indicate that perioperative immunotherapies significantly improved event-free survival (EFS) with a pooled hazard ratio (HR) of 0.58 and increased complete pathological response (pCR) and major pathological response (MPR) rates, with risk differences of 21% and 29%, respectively. These outcomes favored immunotherapies over chemotherapy across varying disease stages, histologies, and PD-L1 expression levels.<br /><br />Regarding safety, no significant difference in the incidence of treatment-related adverse events (TRAE) and surgery-related adverse events between the immunotherapy and chemotherapy groups was observed. Both treatment regimens showed similar surgical outcomes, including resection rates and the type of surgical procedures undertaken.<br /><br />The findings support the use of perioperative immunotherapies in patients with resectable NSCLC, showing improvement in survival metrics without additional safety concerns or surgical complications. This analysis highlights the benefit of incorporating immunotherapies in perioperative treatment plans for patients with resectable NSCLC, offering potential improvements over conventional chemotherapy.

Asset Subtitle

Hongxu Liu

Meta Tag

Speaker Hongxu Liu

Topic Early-Stage NSCLC

Keywords

perioperative immunotherapy

NSCLC

neoadjuvant therapy

adjuvant therapy

chemotherapy

event-free survival

pathological response

treatment safety

lung cancer

immunotherapy efficacy